None
Quote | ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)
Last: | $0.47 |
---|---|
Change Percent: | -0.21% |
Open: | $0.47 |
Close: | $0.47 |
High: | $0.4986 |
Low: | $0.4501 |
Volume: | 1,005,768 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chro...
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Ar...
Message Board Posts | ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)
Subject | By | Source | When |
---|---|---|---|
$ASLN Good read | ClayTrader | investorshub | 07/03/2023 4:51:52 PM |
$ASLN bulls and bears | keekee | investorshub | 07/03/2023 5:08:15 AM |
$ASLN should we be shorting? | keekee | investorshub | 07/03/2023 12:14:05 AM |
Price trading up | senderos | investorshub | 07/02/2023 8:31:34 PM |
The now last up | ALERTS100%to10000%GAIN | investorshub | 06/30/2023 6:45:53 AM |
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused bi...
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chro...
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Ar...